EMEA-002880-PIP01-20-M01 - paediatric investigation plan
COVID-19 vaccine (Ad26.COV2-S (recombinant))
PIP
Human
Janssen-Cilag International N.V.
Tel. +32 14602111
E-mail: contact@Janssen-emea.com